Clinical Trial Update: Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This entry describes a Phase 1/2 trial to assess safety, tolerability, and preliminary efficacy of 161Tb-NYM032 in metastatic castration-resistant prostate canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 161Tb-NYM032

Snippet

Sponsor: Zhengguo Chen | Conditions: Metastatic Castration-resistant Prostate Cancer, MCRPC, Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING